重症急性胰腺炎患者采用乌司他丁与奥曲肽治疗的预后及血流变学指标变化情况
|
摘要
目的探讨重症急性胰腺炎患者采用乌司他丁与奥曲肽治疗的预后及血流变学指标变化情况。方法收集2016年12月至2018年7月本院进行治疗的80例重症急性胰腺炎患者的临床资料,按照治疗方案不同分为观察组40例和对照组40例,两组患者确诊后即给予常规对症治疗,对照组患者给予奥曲肽治疗,观察组患者给予乌司他丁+奥曲肽治疗,比较两组患者疗程结束时预后效果、治疗期间并发症发生情况及治疗前后血流变学指标变化情况。结果观察组患者总有效率高于对照组,差异有统计学意义(P<0.05);观察组患者治疗后全血高切黏度、血浆黏度、血小板黏附率均低于对照组,差异有统计学意义(P<0.05);观察组患者治疗期间并发症总发生率低于对照组,差异有统计学意义(P<0.05)。结论乌司他丁与奥曲肽治疗重症急性胰腺炎疗效显著,可明显改善患者血流变学指标,降低并发症发生风险,值得临床推荐。
Objective To investigate the prognosis and hemorheological changes of patients with severe acute pancreatitis treated with Ulinastatin and octreotide. Methods The clinical data of 80 patients with severe acute pancreatitis treated in our hospital from December 2016 to July2018 were collected and divided into observation group(40 cases) and control group(40 cases) according to different treatment schemes. The patients in the two groups were given routine symptomatic treatment immediately after diagnosis. The patients in the control group were given octreotide treatment. The patients in the observation group were given Ulinastatin + octreotide treatment. The treatment course of the two groups was compared. The prognostic effect, complications during treatment and changes of hemorheological parameters before and after treatment were observed.Results The total effective rate of the observation group was higher than that of the control group, with statistical significance(P<0.05); the whole blood high shear viscosity, plasma viscosity and platelet adhesion rate of the observation group were lower than those of the control group after treatment, with statistical significance(P<0.05); the total incidence of complications of the observation group was lower than that of the control group during treatment, with statistical significance(P<0.05). Conclusion Ulinastatin and octreotide are effective in the treatment of severe acute pancreatitis. They can significantly improve the hemorheological parameters and reduce the risk of complications, which is worthy of clinical recommendation.
Objective To investigate the prognosis and hemorheological changes of patients with severe acute pancreatitis treated with Ulinastatin and octreotide. Methods The clinical data of 80 patients with severe acute pancreatitis treated in our hospital from December 2016 to July2018 were collected and divided into observation group(40 cases) and control group(40 cases) according to different treatment schemes. The patients in the two groups were given routine symptomatic treatment immediately after diagnosis. The patients in the control group were given octreotide treatment. The patients in the observation group were given Ulinastatin + octreotide treatment. The treatment course of the two groups was compared. The prognostic effect, complications during treatment and changes of hemorheological parameters before and after treatment were observed.Results The total effective rate of the observation group was higher than that of the control group, with statistical significance(P<0.05); the whole blood high shear viscosity, plasma viscosity and platelet adhesion rate of the observation group were lower than those of the control group after treatment, with statistical significance(P<0.05); the total incidence of complications of the observation group was lower than that of the control group during treatment, with statistical significance(P<0.05). Conclusion Ulinastatin and octreotide are effective in the treatment of severe acute pancreatitis. They can significantly improve the hemorheological parameters and reduce the risk of complications, which is worthy of clinical recommendation.
引文
[1]杨韬.奥曲肽治疗急性胰腺炎30例临床疗效分析[J].当代医学,2013,19(10):104-105.
[2]李梁,郑立君.乌司他丁治疗急性重症胰腺炎的meta分析[J].同济大学学报(医学版),2013,34(1):62-68.
[3]王丰平,张永龙.乌司他丁联合生长抑素治疗急性重症胰腺炎疗效观察[J].中国药师,2014,17(5):812-814.
[4]王春友,李非,赵玉沛,等.急性胰腺炎诊治指南(2014)[J].临床肝胆病杂志,2015,31(1):17-20.
[5]冯冬梅.消化内科治疗急性胰腺炎的临床体会[J].当代医学,2017,23(5):53-54.
[6]磨庆福.重症急性胰腺炎的发病原因及发病机制研究进展[J].胃肠病学和肝病学杂志,2014,23(9):1107-1110.
[7]颜庆余.重症急性胰腺炎治疗方法新进展研究[J].中国疗养医学,2016,25(2):130-132.
[8]雷正元,罗恒丽,王国俊.奥曲肽联合大黄治疗急性胰腺炎的Meta分析[J].重庆医学,2015,44(24):3385-3388,3392.
[9]曾杰,陈宁波,胡卫健.奥曲肽联合加贝酯治疗重症急性胰腺炎的疗效及对患者胃肠功能和血清细胞因子的影响[J].中国老年学杂志,2014,34(17):4743-4745.
[10]王飞,杨春琴,吴水强,等.乌司他丁联合生长抑素治疗急性胰腺炎的疗效[J].中国生化药物杂志,2016,36(1):154-156.
[11]秦林燕,王国兴.乌司他丁联合生长抑素对重症急性胰腺炎大鼠血清炎性细胞因子的影响[J].临床和实验医学杂志,2015,14(15):1225-1228.
[12]刘国兴.重症急性胰腺炎病因及发病机制研究进展[J].世界最新医学信息文摘,2017,17(71):48.
[2]李梁,郑立君.乌司他丁治疗急性重症胰腺炎的meta分析[J].同济大学学报(医学版),2013,34(1):62-68.
[3]王丰平,张永龙.乌司他丁联合生长抑素治疗急性重症胰腺炎疗效观察[J].中国药师,2014,17(5):812-814.
[4]王春友,李非,赵玉沛,等.急性胰腺炎诊治指南(2014)[J].临床肝胆病杂志,2015,31(1):17-20.
[5]冯冬梅.消化内科治疗急性胰腺炎的临床体会[J].当代医学,2017,23(5):53-54.
[6]磨庆福.重症急性胰腺炎的发病原因及发病机制研究进展[J].胃肠病学和肝病学杂志,2014,23(9):1107-1110.
[7]颜庆余.重症急性胰腺炎治疗方法新进展研究[J].中国疗养医学,2016,25(2):130-132.
[8]雷正元,罗恒丽,王国俊.奥曲肽联合大黄治疗急性胰腺炎的Meta分析[J].重庆医学,2015,44(24):3385-3388,3392.
[9]曾杰,陈宁波,胡卫健.奥曲肽联合加贝酯治疗重症急性胰腺炎的疗效及对患者胃肠功能和血清细胞因子的影响[J].中国老年学杂志,2014,34(17):4743-4745.
[10]王飞,杨春琴,吴水强,等.乌司他丁联合生长抑素治疗急性胰腺炎的疗效[J].中国生化药物杂志,2016,36(1):154-156.
[11]秦林燕,王国兴.乌司他丁联合生长抑素对重症急性胰腺炎大鼠血清炎性细胞因子的影响[J].临床和实验医学杂志,2015,14(15):1225-1228.
[12]刘国兴.重症急性胰腺炎病因及发病机制研究进展[J].世界最新医学信息文摘,2017,17(71):48.